Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by tau and amyloid protein aggregation, leading to neurodegeneration and cognitive decline.
• Pathological tau aggregates spread in the brain via a "prion-like" mechanism, contributing significantly to AD pathology.
• Therapeutic antibodies targeting extracellular tau are a promising strategy, potentially working by enabling microglial clearance of these aggregates.

Purpose of the Study:

• To develop and validate a quantitative cell-based assay for assessing microglial uptake of tau aggregates.
• To provide a tool for characterizing the effector functions of anti-tau antibodies in the context of microglial-mediated clearance.

Main Methods:

• Utilized the mouse microglial cell line BV-2 in a quantitative cell-based assay.
• Focused on measuring the uptake of aggregated tau species by these microglial cells.
• Designed for high specificity, low variability, and medium-throughput data generation.

Main Results:

• Successfully established a reliable cell-based assay for quantifying tau uptake by microglia.
• The assay demonstrates high specificity and low variability, suitable for medium-throughput screening.
• Generated data can inform the characterization of anti-tau antibody efficacy.

Conclusions:

• The developed assay is a valuable tool for studying microglial interactions with pathological tau.
• This assay can aid in the development and characterization of novel immunotherapies for Alzheimer's disease.
• Understanding tau uptake by microglia is crucial for developing effective treatments to interrupt disease progression.